Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.

Autor:	Garcia MM; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Varela CG; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Silva PF; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Lima PR; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Góes PM; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Rodrigues MG; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Silva Mde L; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Ladeia AM; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Guimarães AC; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil., Correia LC; Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil.
Jazyk:	English; Portuguese
Zdroj:	Arquivos brasileiros de cardiologia [Arq Bras Cardiol] 2016 Apr; Vol. 106 (4), pp. 279-88.
DOI:	10.5935/abc.20160048
Abstrakt:	Background: The effect of statins on the endothelial function in humans remains under discussion. Particularly, it is still unclear if the improvement in endothelial function is due to a reduction in LDL-cholesterol or to an arterial pleiotropic effect. Objective: To test the hypothesis that modulation of the endothelial function promoted by statins is primarily mediated by the degree of reduction in LDL-cholesterol, independent of the dose of statin administered. Methods: Randomized clinical trial with two groups of lipid-lowering treatment (16 patients/each) and one placebo group (14 patients). The two active groups were designed to promote a similar degree of reduction in LDL-cholesterol: the first used statin at a high dose (80 mg, simvastatin 80 group) and the second used statin at a low dose (10 mg) associated with ezetimibe (10 mg, simvastatin 10/ezetimibe group) to optimize the hypolipidemic effect. The endothelial function was assessed by flow-mediated vasodilation (FMV) before and 8 weeks after treatment. Results: The decrease in LDL-cholesterol was similar between the groups simvastatin 80 and simvastatin 10/ezetimibe (27% ± 31% and 30% ± 29%, respectively, p = 0.75). The simvastatin 80 group presented an increase in FMV from 8.4% ± 4.3% at baseline to 11% ± 4.2% after 8 weeks (p = 0.02). Similarly, the group simvastatin 10/ezetimibe showed improvement in FMV from 7.3% ± 3.9% to 12% ± 4.4% (p = 0.001). The placebo group showed no variation in LDL-cholesterol level or endothelial function. Conclusion: The improvement in endothelial function with statin seems to depend more on a reduction in LDL-cholesterol levels, independent of the dose of statin administered, than on pleiotropic mechanisms.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu